株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

黒色腫:パイプライン製品の分析

Melanoma - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 232839
出版日 ページ情報 英文 2285 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.91円で換算しております。
Back to Top
黒色腫:パイプライン製品の分析 Melanoma - Pipeline Review, H2 2018
出版日: 2018年12月21日 ページ情報: 英文 2285 Pages
概要

黒色腫とは、メラニン細胞の悪性転換の結果発達した腫瘍です。これらの細胞は神経堤から派生したものであり、黒色腫は通常皮膚上に現れますが、神経堤が移動(遊走)した場所、例えば消化管や脳にも起こることがあります。男性よりも女性によく見られ、特に女性の足や男性の背中に出ることが多いようです。皮膚上にほくろ、痛い場所、かたまり、傷、模様などが目立って見られたり感じられたりする場合は黒色腫の徴候です。治療法は手術や放射線および陽子線治療などです。

当レポートでは、黒色腫の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 黒色腫 概要

治療薬の開発

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

治療薬の評価

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

図表

List of Tables

  • Number of Products under Development for Melanoma, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Melanoma - Pipeline by 4D Pharma PLC, H2 2018
  • Melanoma - Pipeline by 4P-Pharma SAS, H2 2018
  • Melanoma - Pipeline by 4SC AG, H2 2018
  • Melanoma - Pipeline by AB Science SA, H2 2018
  • Melanoma - Pipeline by AbbVie Inc, H2 2018
  • Melanoma - Pipeline by Abivax SA, H2 2018
  • Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2018
  • Melanoma - Pipeline by Aduro BioTech Inc, H2 2018
  • Melanoma - Pipeline by Advanced BioDesign, H2 2018
  • Melanoma - Pipeline by Advenchen Laboratories LLC, H2 2018
  • Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H2 2018
  • Melanoma - Pipeline by Afecta Pharmaceuticals Inc, H2 2018
  • Melanoma - Pipeline by Affichem SA, H2 2018
  • Melanoma - Pipeline by Agenus Inc, H2 2018
  • Melanoma - Pipeline by AGV Discovery SAS, H2 2018
  • Melanoma - Pipeline by AIMM Therapeutics BV, H2 2018
  • Melanoma - Pipeline by AiVita Biomedical Inc, H2 2018
  • Melanoma - Pipeline by Alkermes Plc, H2 2018
  • Melanoma - Pipeline by Allergy Therapeutics Plc, H2 2018
  • Melanoma - Pipeline by Alligator Bioscience AB, H2 2018
  • Melanoma - Pipeline by Altor BioScience Corp, H2 2018
  • Melanoma - Pipeline by Amgen Inc, H2 2018
  • Melanoma - Pipeline by Angimmune LLC, H2 2018
  • Melanoma - Pipeline by Antibe Therapeutics Inc, H2 2018
  • Melanoma - Pipeline by APEIRON Biologics AG, H2 2018
  • Melanoma - Pipeline by Apexigen Inc, H2 2018
  • Melanoma - Pipeline by Aphios Corp, H2 2018
  • Melanoma - Pipeline by Aposense Ltd, H2 2018
  • Melanoma - Pipeline by Aprea AB, H2 2018
  • Melanoma - Pipeline by Aptose Biosciences Inc, H2 2018
  • Melanoma - Pipeline by Arcus Biosciences Inc, H2 2018
  • Melanoma - Pipeline by ArQule Inc, H2 2018
  • Melanoma - Pipeline by Array BioPharma Inc, H2 2018
  • Melanoma - Pipeline by Asana BioSciences LLC, H2 2018
  • Melanoma - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2018
  • Melanoma - Pipeline by Astex Pharmaceuticals Inc, H2 2018
  • Melanoma - Pipeline by Atreca Inc, H2 2018
  • Melanoma - Pipeline by aTyr Pharma Inc, H2 2018
  • Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
  • Melanoma - Pipeline by Autolus Therapeutics Plc, H2 2018
  • Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H2 2018
  • Melanoma - Pipeline by Batu Biologics Inc, H2 2018
  • Melanoma - Pipeline by Bayer AG, H2 2018
  • Melanoma - Pipeline by BeiGene Ltd, H2 2018
  • Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2018
  • Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2018
  • Melanoma - Pipeline by BerGenBio ASA, H2 2018

List of Figures

  • Number of Products under Development for Melanoma, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018
目次
Product Code: GMDHC11021IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H2 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 18, 126, 141, 1, 11, 223, 33 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 18, 16, 75 and 11 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Melanoma - Overview
  • Melanoma - Therapeutics Development
  • Melanoma - Therapeutics Assessment
  • Melanoma - Companies Involved in Therapeutics Development
  • Melanoma - Drug Profiles
  • Melanoma - Dormant Projects
  • Melanoma - Discontinued Products
  • Melanoma - Product Development Milestones
  • Appendix
Back to Top